InforMax Announces Genomax(TM) License Agreement With Cellular Genomics, Inc.
PR NEWSWIRE - May 14, 2001 14:38
BETHESDA, Md., May 14, 2001 /PRNewswire via COMTEX/ -- InforMax, Inc. (Nasdaq: INMX), a leading global provider of bioinformatics software solutions, today announced that in the first quarter ending March 31, 2001 it signed a license agreement with Cellular Genomics, Inc. for GenoMax(TM) enterprise software.
(Photo: newscom.com )
Rapidly becoming an industry standard, GenoMax(TM) is an enterprise bioinformatics system that supports High-Throughput Research(TM) (HTR), InforMax's process for minimizing the time and cost of both discovering and validating valuable targets for pharmaceutical, therapeutic, and diagnostic development. GenoMax(TM) is a modular family of tools, each designed specifically to work with one or more types of genomic and proteomic data, including sequence information, gene expression data, and protein structure. The GenoMax enterprise platform has been sold to over 30 pharmaceutical, biotechnology, and academic customers.
"We are very pleased to be working with InforMax and their GenoMax software products," said Andy Whitney, Ph.D., Director of Bioinformatics for Cellular Genomics Inc. "These products will form a key element of CGI's bioinformatics infrastructure, allowing us to rapidly meet our needs of high throughput sequence analysis for our protein-protein interaction screens, as well as gene expression analysis for our target validation work. The modular architecture of GenoMax will allow us to integrate additional tools and databases as we move forward in our drug discovery efforts." "We are pleased that more and more organizations are relying on GenoMax and our High- Throughput Research approach to discovery research to optimize their research programs," said Alex Titomirov, Ph.D., InforMax chief executive officer and chairman. "We look forward to helping Cellular Genomics enhance their discovery efforts." |
